These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9194649)

  • 21. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss.
    Strawford A; Barbieri T; Neese R; Van Loan M; Christiansen M; Hoh R; Sathyan G; Skowronski R; King J; Hellerstein M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Feb; 20(2):137-46. PubMed ID: 10048900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 7α-methyl-19-nortestosterone vs. testosterone implants for hypogonadal osteoporosis: a preclinical study in the aged male orchidectomized rat model.
    Sinnesael M; Callewaert F; Morreels M; Kumar N; Sitruk-Ware R; Van Proeyen K; Hespel P; Boonen S; Claessens F; Vanderschueren D
    Int J Androl; 2011 Dec; 34(6 Pt 2):e601-11. PubMed ID: 21790658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 28 Days of Oral Dimethandrolone Undecanoate in Healthy Men: A Prototype Male Pill.
    Thirumalai A; Ceponis J; Amory JK; Swerdloff R; Surampudi V; Liu PY; Bremner WJ; Harvey E; Blithe DL; Lee MS; Hull L; Wang C; Page ST
    J Clin Endocrinol Metab; 2019 Feb; 104(2):423-432. PubMed ID: 30252061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study.
    Erb K; Pechstein B; Schueler A; Engel J; Hermann R
    Clin Pharmacol Ther; 2000 Jun; 67(6):660-9. PubMed ID: 10872648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-androgen TSAA-291. IV. Effects of the anti-androgen TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) on the secretion of gonadotrophins.
    Sudo K; Yamazaki I; Masuoka M; Nakayama R
    Acta Endocrinol Suppl (Copenh); 1979; 229():53-66. PubMed ID: 294107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of 19-nortestosterone esters in normal men.
    Belkien L; Schürmeyer T; Hano R; Gunnarsson PO; Nieschlag E
    J Steroid Biochem; 1985 May; 22(5):623-9. PubMed ID: 4010287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of male sexual behavior in the rat by 7 alpha-methyl-19-nortestosterone, an androgen that does not undergo 5 alpha-reduction.
    Moralí G; Lemus AE; Munguía R; Arteaga M; Pérez-Palacios G; Sundaram K; Kumar N; Bardin CW
    Biol Reprod; 1993 Sep; 49(3):577-81. PubMed ID: 8399852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of single-dose nandrolone decanoate on gonadotropins, blood lipids and HMG CoA reductase in healthy men.
    Gårevik N; Börjesson A; Choong E; Ekström L; Lehtihet M
    Andrologia; 2016 Jun; 48(5):595-600. PubMed ID: 26370185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase.
    Attardi BJ; Pham TC; Radler LC; Burgenson J; Hild SA; Reel JR
    J Steroid Biochem Mol Biol; 2008 Jun; 110(3-5):214-22. PubMed ID: 18555683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men.
    Wu S; Yuen F; Swerdloff RS; Pak Y; Thirumalai A; Liu PY; Amory JK; Bai F; Hull L; Blithe DL; Anawalt BD; Parman T; Kim K; Lee MS; Bremner WJ; Page ST; Wang C
    J Clin Endocrinol Metab; 2019 Mar; 104(3):629-638. PubMed ID: 30252057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance.
    Friedl KE; Jones RE; Hannan CJ; Plymate SR
    J Clin Endocrinol Metab; 1989 May; 68(5):971-5. PubMed ID: 2654171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effects of dimethandrolone 17β-undecanoate and 11β-methyl-19-nortestosterone 17β-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats.
    Attardi BJ; Marck BT; Matsumoto AM; Koduri S; Hild SA
    J Androl; 2011; 32(2):183-92. PubMed ID: 20798389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 7alpha-methyl-19-nortestosterone (MENT): the optimal androgen for male contraception and replacement therapy.
    Sundaram K; Kumar N
    Int J Androl; 2000; 23 Suppl 2():13-5. PubMed ID: 10849485
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of gonadotropin-releasing hormone pulse-frequency modulation on luteinizing hormone, follicle-stimulating hormone and testosterone secretion in hypothalamo/pituitary-disconnected rams.
    Wu FC; Irby DC; Clarke IJ; Cummins JT; de Kretser DM
    Biol Reprod; 1987 Oct; 37(3):501-10. PubMed ID: 3118979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen.
    Bhasin S; Yuan QX; Steiner BS; Swerdloff RS
    J Clin Endocrinol Metab; 1987 Sep; 65(3):568-74. PubMed ID: 3114307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men.
    Anderson RA; Wallace AM; Sattar N; Kumar N; Sundaram K
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2784-93. PubMed ID: 12788888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.